119O Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after ≥4 years of follow-up: BrighTNess, a randomized phase III trial

Sibylle Loibl, William M. Sikov, Jens Huober, Hope S. Rugo, Norman Wolmark, Joyce O’Shaughnessy, David Maag, Michael Untch, Mehra Golshan, J. Ponce Lorenzo, Otto Metzger, Martin Dunbar, W. Fraser Symmans, Charles E. Geyer